Sign In
Buy SNDX
$18.34
-0.0500 (-0.272%)
At Close: Jun 03, 2026
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia October 24, 2025 2:30 PM EDT Company Participants Sharon K
– First and only therapy FDA approved in both R/R acute myeloid leukemia (AML) with an NPM1 mutation and R/R acute leukemia with a KMT2A translocation –
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of “Moderate Buy” by Analysts
01:42am, Friday, 24'th Oct 2025
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eleven research firms that are presently covering the company, MarketBea
3 Biotech Stocks I Am Accumulating
02:30pm, Wednesday, 15'th Oct 2025
The biotech sector has underperformed the market for many years now, but there are reasons to be optimistic about this area of the market. Many biotech/biopharma stocks also make good covered call tra
Making Money In Biotech Stocks
05:00pm, Thursday, 09'th Oct 2025
How to trade and invest in the biotech space, according to ROTY Biotech Community's Jonathan Faison. Favoring late-stage, commercial-stage companies with clear paths to profitability and strong sales
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:01pm, Friday, 03'rd Oct 2025
NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on October
3 Potential Biotech Acquisition Targets
12:53pm, Friday, 19'th Sep 2025
There has been some speculation on Seeking Alpha recently on several biotech/biopharma names that make logical buyout targets. Many firms are on their way to success as standalone entities and have go
NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Nationa
Syndax Pharmaceuticals: Revumenib PDUFA Review mNPM1 AML And Move Towards MSS CRC
06:10pm, Wednesday, 10'th Sep 2025
FDA approval of revumenib for r/r KMT2Ar AML patients drives strong revenue growth for Syndax Pharmaceuticals, with Q2 2025 sales up 43% quarter-over-quarter. Upcoming FDA Priority Review decision for
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:01pm, Friday, 05'th Sep 2025
NEW YORK, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on Septemb
Syndax Pharmaceuticals, Inc. (SNDX) Presents At Citi's Biopharma Back To School Conference Transcript
07:50pm, Tuesday, 02'nd Sep 2025
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX ) Citi's Biopharma Back to School Conference September 2, 2025 4:45 PM EDT Company Participants Keith Goldan - CFO, Treasurer & Chief Accounting Officer Steve
Wall Street Analysts Believe Syndax (SNDX) Could Rally 112.8%: Here's is How to Trade
10:56am, Monday, 01'st Sep 2025
The mean of analysts' price targets for Syndax (SNDX) points to an 112.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst
Syndax Announces Participation in September Investor Conferences
07:00am, Tuesday, 26'th Aug 2025
NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. M
Does Syndax (SNDX) Have the Potential to Rally 158.36% as Wall Street Analysts Expect?
10:56am, Thursday, 14'th Aug 2025
The mean of analysts' price targets for Syndax (SNDX) points to a 158.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts
Syndax Pharmaceuticals: A Tale Of Two Drug Launches
06:34pm, Wednesday, 13'th Aug 2025
Shares of Syndax Pharmaceuticals are still down 45% over the past three years. The Q2 report was encouraging on multiple fronts with a strong start for the Revuforj launch in KMT2A AML and Niktimvo la
